vs
Astrana Health, Inc.（ASTH）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
Astrana Health, Inc.の直近四半期売上が大きい（$950.5M vs $790.2M、UNITED THERAPEUTICS Corpの約1.2倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 0.7%、差は45.4%）。Astrana Health, Inc.の前年同期比売上増加率が高い（42.9% vs 7.4%）。UNITED THERAPEUTICS Corpの直近四半期フリーキャッシュフローが多い（$173.3M vs $-6.0M）。過去8四半期でAstrana Health, Inc.の売上複合成長率が高い（53.3% vs 8.0%）
アストラナヘルス社は米国に本拠を置く価値基準型医療サービスプロバイダーで、主に米国全土の連邦医療保険対象高齢者層にサービスを提供している。訪問型プライマリケア、慢性疾患管理、ケアコーディネーションを通じ、患者の健康状態改善と不要な医療費削減を目指している。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
ASTH vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $950.5M | $790.2M |
| 純利益 | $6.6M | $364.3M |
| 粗利率 | — | 86.9% |
| 営業利益率 | 1.9% | 45.1% |
| 純利益率 | 0.7% | 46.1% |
| 売上前年比 | 42.9% | 7.4% |
| 純利益前年比 | 184.4% | 20.9% |
| EPS（希薄化後） | $0.12 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $950.5M | $790.2M | ||
| Q3 25 | $956.0M | $799.5M | ||
| Q2 25 | $654.8M | $798.6M | ||
| Q1 25 | $620.4M | $794.4M | ||
| Q4 24 | $665.2M | $735.9M | ||
| Q3 24 | $478.7M | $748.9M | ||
| Q2 24 | $486.3M | $714.9M | ||
| Q1 24 | $404.4M | $677.7M |
| Q4 25 | $6.6M | $364.3M | ||
| Q3 25 | $373.0K | $338.7M | ||
| Q2 25 | $9.4M | $309.5M | ||
| Q1 25 | $6.7M | $322.2M | ||
| Q4 24 | $-7.8M | $301.3M | ||
| Q3 24 | $16.1M | $309.1M | ||
| Q2 24 | $19.2M | $278.1M | ||
| Q1 24 | $14.8M | $306.6M |
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 87.4% | ||
| Q2 25 | — | 89.0% | ||
| Q1 25 | — | 88.4% | ||
| Q4 24 | — | 89.7% | ||
| Q3 24 | — | 88.9% | ||
| Q2 24 | — | 89.1% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 1.9% | 45.1% | ||
| Q3 25 | 2.0% | 48.6% | ||
| Q2 25 | 3.1% | 45.6% | ||
| Q1 25 | 3.3% | 48.2% | ||
| Q4 24 | 0.1% | 48.6% | ||
| Q3 24 | 5.9% | 45.8% | ||
| Q2 24 | 6.2% | 44.7% | ||
| Q1 24 | 7.5% | 52.6% |
| Q4 25 | 0.7% | 46.1% | ||
| Q3 25 | 0.0% | 42.4% | ||
| Q2 25 | 1.4% | 38.8% | ||
| Q1 25 | 1.1% | 40.6% | ||
| Q4 24 | -1.2% | 40.9% | ||
| Q3 24 | 3.4% | 41.3% | ||
| Q2 24 | 3.9% | 38.9% | ||
| Q1 24 | 3.7% | 45.2% |
| Q4 25 | $0.12 | $7.66 | ||
| Q3 25 | $0.01 | $7.16 | ||
| Q2 25 | $0.19 | $6.41 | ||
| Q1 25 | $0.14 | $6.63 | ||
| Q4 24 | $-0.14 | $6.23 | ||
| Q3 24 | $0.33 | $6.39 | ||
| Q2 24 | $0.40 | $5.85 | ||
| Q1 24 | $0.31 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $429.5M | $2.9B |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $779.3M | $7.1B |
| 総資産 | $2.2B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $429.5M | $2.9B | ||
| Q3 25 | $463.4M | $2.8B | ||
| Q2 25 | $342.1M | $3.0B | ||
| Q1 25 | $260.9M | $3.3B | ||
| Q4 24 | $290.8M | $3.3B | ||
| Q3 24 | $350.3M | $3.3B | ||
| Q2 24 | $327.7M | $3.0B | ||
| Q1 24 | $337.3M | $2.7B |
| Q4 25 | $779.3M | $7.1B | ||
| Q3 25 | $775.5M | $6.6B | ||
| Q2 25 | $765.5M | $7.2B | ||
| Q1 25 | $745.4M | $6.8B | ||
| Q4 24 | $712.7M | $6.4B | ||
| Q3 24 | $704.6M | $6.1B | ||
| Q2 24 | $678.9M | $5.7B | ||
| Q1 24 | $653.5M | $5.3B |
| Q4 25 | $2.2B | $7.9B | ||
| Q3 25 | $2.2B | $7.4B | ||
| Q2 25 | $1.4B | $7.9B | ||
| Q1 25 | $1.3B | $7.7B | ||
| Q4 24 | $1.4B | $7.4B | ||
| Q3 24 | $1.3B | $7.1B | ||
| Q2 24 | $1.3B | $6.7B | ||
| Q1 24 | $1.2B | $6.5B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $-2.9M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $-6.0M | $173.3M |
| FCFマージンFCF / 売上 | -0.6% | 21.9% |
| 設備投資強度設備投資 / 売上 | 0.3% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | -0.44× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $104.5M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $-2.9M | $346.2M | ||
| Q3 25 | $10.0M | $562.1M | ||
| Q2 25 | $90.9M | $191.7M | ||
| Q1 25 | $16.6M | $461.2M | ||
| Q4 24 | $-10.9M | $341.2M | ||
| Q3 24 | $34.0M | $377.2M | ||
| Q2 24 | $23.2M | $232.2M | ||
| Q1 24 | $6.0M | $376.5M |
| Q4 25 | $-6.0M | $173.3M | ||
| Q3 25 | $7.4M | $351.6M | ||
| Q2 25 | $89.5M | $129.5M | ||
| Q1 25 | $13.6M | $386.3M | ||
| Q4 24 | $-13.5M | $254.5M | ||
| Q3 24 | $31.7M | $300.7M | ||
| Q2 24 | $20.4M | $187.1M | ||
| Q1 24 | $5.6M | $338.3M |
| Q4 25 | -0.6% | 21.9% | ||
| Q3 25 | 0.8% | 44.0% | ||
| Q2 25 | 13.7% | 16.2% | ||
| Q1 25 | 2.2% | 48.6% | ||
| Q4 24 | -2.0% | 34.6% | ||
| Q3 24 | 6.6% | 40.2% | ||
| Q2 24 | 4.2% | 26.2% | ||
| Q1 24 | 1.4% | 49.9% |
| Q4 25 | 0.3% | 21.9% | ||
| Q3 25 | 0.3% | 26.3% | ||
| Q2 25 | 0.2% | 7.8% | ||
| Q1 25 | 0.5% | 9.4% | ||
| Q4 24 | 0.4% | 11.8% | ||
| Q3 24 | 0.5% | 10.2% | ||
| Q2 24 | 0.6% | 6.3% | ||
| Q1 24 | 0.1% | 5.6% |
| Q4 25 | -0.44× | 0.95× | ||
| Q3 25 | 26.69× | 1.66× | ||
| Q2 25 | 9.65× | 0.62× | ||
| Q1 25 | 2.48× | 1.43× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | 2.11× | 1.22× | ||
| Q2 24 | 1.21× | 0.83× | ||
| Q1 24 | 0.40× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
